Invibio, Part of Victrex plc, Announces New Collaboration With Paragon Medical to Support Scale Up of PEEK Based Trauma Devices

Invibio Biomaterial Solutions, part of Victrex plc, a pioneer in the development of PEEK biomaterial solutions, today announced a new collaboration with Paragon Medical, a medical device contract design manufacturer with over a century of combined expertise in high-precision manufacturing, advanced engineering and design support, to manufacture composite PEEK-OPTIMA™ Ultra-Reinforced medical trauma devices.

The manufacturing arrangement with Paragon Medical will support the scale up of high quality PEEK-OPTIMA™ ultra-reinforced composite fracture fixation devices, at a time when Invibio is seeing demand exceeding initial expectations.

The announcement coincides with Paragon Medical’s recent expansion of dedicated space for this collaboration in their manufacturing facility in Changzhou, China.

Investing in the future of Invibio PEEK-OPTIMA™ Ultra-Reinforced composite devices

Invibio has extensive experience in collaborating with customers in PEEK-OPTIMA™ Ultra-Reinforced part design and process development, with significant know-how and intellectual property (IP). During this time Invibio has developed novel materials and IP in relation to optimising the design and development of these parts and supporting customers with regulatory approval.

“We are delighted to be working with Invibio to increase production of their innovative devices which can help to drive improved patient outcomes globally,” says Wil Boren, Paragon Medical CEO.

Providing scale, quality, confidence and manufacturing flexibility

The recent opening of the Invibio Leeds orthopedic product development centre in the UK has the potential to support an increase in the speed at which medical device companies can develop new PEEK-OPTIMA™ Ultra-Reinforced composite fracture fixation devices.

The Paragon Medical collaboration can provide Invibio customers with additional world class medical composite manufacturing facilities to help serve growing customer demand for these products.

“Trauma is one of Victrex’s key mega-programmes, where we see significant growth opportunities over the years ahead and the opportunity to enhance patient outcomes. Clinical data on PEEK based trauma plates is already encouraging and initial demand is exceeding our expectations. We have invested over several years now, and bring a wealth of intellectual property in this area. Paragon Medical will help us support manufacturing scale up, and they bring an excellent reputation as one of the world’s premier medical contract manufacturers. We are delighted to work with them to grow the composite trauma space and to make it easier for medical device companies to adopt this technology,” explains Jakob Sigurdsson, CEO of Victrex.

“With a broad operating footprint in Europe, China and America, Paragon Medical are an attractive company to work with, dealing with evolving supply chain strategies within the medical device industry.”

PEEK-OPTIMA™ Ultra-Reinforced composite device benefits

Patient risk factors affecting fracture healing such as diabetes, osteoporosis or obesity have increased significantly in recent years, which has in turn increased the challenges for traditional titanium plates and nails to successfully heal patients. The increased risk of delayed union or non-union may be reduced by utilising plates made from PEEK-OPTIMA™ Ultra-Reinforced materials due to their increased fatigue lifetime and the ability to tailor the stiffness of the device.*

PEEK based medical devices have been successfully implanted for over twenty years. The benefits of PEEK OPTIMA Ultra reinforced trauma plates such as increased fatigue lifetime, tailored stiffness and improved imaging are now being utilised to treat a more challenging patient population.*

The potential to reduce revisions and accelerate healing make these solutions attractive to surgeons, patients and to payors.

SourceInvibio

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”